DiaMedica Therapeutics Upcoming Conference Participation
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences in September. The company, which focuses on developing recombinant KLK1 (DM199) for acute ischemic stroke and preeclampsia treatment, will attend:
- HC Wainwright Global Investment Conference (September 9-11, New York): Presenting on September 9th at 3:00-3:30 PM ET
- Lake Street Best Ideas Growth Conference Big 8 (September 12, New York): Participating in one-on-one meetings
DiaMedica's lead candidate, DM199, is the first pharmaceutically active recombinant form of the KLK1 protein, an established therapeutic modality in Asia for treating acute ischemic stroke and other vascular diseases. Investors interested in meeting with DiaMedica's management can contact their account representatives to arrange meetings.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), un'azienda biopharmaceutica in fase clinica, ha annunciato la sua partecipazione a due prossime conferenze per investitori a settembre. L'azienda, che si concentra sullo sviluppo di KLK1 ricombinante (DM199) per il trattamento di ictus ischemico acuto e preeclampsia, parteciperà a:
- HC Wainwright Global Investment Conference (9-11 settembre, New York): Presentazione il 9 settembre dalle 15:00 alle 15:30 ET
- Lake Street Best Ideas Growth Conference Big 8 (12 settembre, New York): Partecipazione a incontri one-on-one
Il principale candidato di DiaMedica, DM199, è la prima forma ricombinante farmacologicamente attiva della proteina KLK1, una modalità terapeutica consolidata in Asia per il trattamento di ictus ischemico acuto e altre malattie vascolari. Gli investitori interessati a incontrare il management di DiaMedica possono contattare i propri rappresentanti per organizzare incontri.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), una empresa biofarmacéutica en etapa clínica, ha anunciado su participación en dos próximas conferencias para inversores en septiembre. La compañía, que se centra en el desarrollo de KLK1 recombinante (DM199) para el tratamiento de accidente cerebrovascular isquémico agudo y preeclampsia, asistirá a:
- HC Wainwright Global Investment Conference (9-11 de septiembre, Nueva York): Presentación el 9 de septiembre de 3:00 a 3:30 PM ET
- Lake Street Best Ideas Growth Conference Big 8 (12 de septiembre, Nueva York): Participación en reuniones uno a uno
El principal candidato de DiaMedica, DM199, es la primera forma recombinante farmacológicamente activa de la proteína KLK1, una modalidad terapéutica establecida en Asia para tratar el accidente cerebrovascular isquémico agudo y otras enfermedades vasculares. Los inversores interesados en reunirse con la dirección de DiaMedica pueden contactar a sus representantes de cuenta para organizar reuniones.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC)는 임상 단계의 생명공학 회사로, 9월에 있을 두 개의 투자자 회의에 참여할 것임을 발표했습니다. 급성 허혈성 뇌졸중과 자간전증 치료를 위한 KLK1 재조합체(DM199) 개발에 주력하는 이 회사는 다음 회의에 참석할 예정입니다:
- HC Wainwright Global Investment Conference (9월 9-11일, 뉴욕): 9월 9일 오후 3:00-3:30 ET에 발표
- Lake Street Best Ideas Growth Conference Big 8 (9월 12일, 뉴욕): 일대일 미팅 참여
DiaMedica의 주요 후보물질인 DM199는 KLK1 단백질의 첫 번째 약리 활성화된 재조합 형태로, 급성 허혈성 뇌졸중 및 기타 혈관 질환 치료를 위해 아시아에서 확립된 치료 방법입니다. DiaMedica 경영진과의 만남에 관심이 있는 투자자는 회의 일정을 조정하기 위해 담당자에게 연락할 수 있습니다.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à deux prochaines conférences pour investisseurs en septembre. L'entreprise, qui se concentre sur le développement de KLK1 recombiné (DM199) pour le traitement de l'accident vasculaire cérébral ischémique aigu et de la prééclampsie, assistera :
- HC Wainwright Global Investment Conference (9-11 septembre, New York) : Présentation le 9 septembre de 15h00 à 15h30 heure de l'Est
- Lake Street Best Ideas Growth Conference Big 8 (12 septembre, New York) : Participation à des réunions individuelles
Le principal candidat de DiaMedica, DM199, est la première forme recombinante pharmaceutiquement active de la protéine KLK1, une modalité thérapeutique établie en Asie pour le traitement de l'accident vasculaire cérébral ischémique aigu et d'autres maladies vasculaires. Les investisseurs intéressés à rencontrer la direction de DiaMedica peuvent contacter leurs représentants de compte pour organiser des réunions.
Die DiaMedica Therapeutics Inc. (Nasdaq: DMAC), ein biopharmazeutisches Unternehmen in klinischer Phase, hat ihre Teilnahme an zwei bevorstehenden Investorenkonferenzen im September angekündigt. Das Unternehmen, das sich auf die Entwicklung von rekombinantem KLK1 (DM199) zur Behandlung von akutem ischämischem Schlaganfall und Präeklampsie konzentriert, wird an folgenden Veranstaltungen teilnehmen:
- HC Wainwright Global Investment Conference (9.-11. September, New York): Präsentation am 9. September von 15:00 bis 15:30 Uhr ET
- Lake Street Best Ideas Growth Conference Big 8 (12. September, New York): Teilnahme an Einzelgesprächen
Der Hauptkandidat von DiaMedica, DM199, ist die erste pharmakologisch aktive rekombinante Form des KLK1-Proteins, einer in Asien etablierten therapeutischen Modalität zur Behandlung von akutem ischämischem Schlaganfall und anderen Gefäßerkrankungen. Investoren, die an einem Treffen mit dem Management von DiaMedica interessiert sind, können ihre Account-Vertreter kontaktieren, um Treffen zu arrangieren.
- None.
- None.
-
HC Wainwright Global Investment Conference, September 9-11,
New York – Management will present in person on Monday, September 9th at 3:00-3:30 PM ET and participate in one-on-one meetings. -
Lake Street Best Ideas Growth Conference Big 8, September 12,
New York – Management will participate in one-on-one meetings.
Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their respective account representatives to arrange a meeting.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904682546/en/
Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Source: DiaMedica Therapeutics Inc.
FAQ
What conferences will DiaMedica Therapeutics (DMAC) attend in September 2024?
What is DiaMedica Therapeutics' (DMAC) lead candidate and its purpose?
When and where will DiaMedica Therapeutics (DMAC) present at the HC Wainwright conference?
What type of meetings will DiaMedica Therapeutics (DMAC) participate in at the Lake Street conference?
How can investors arrange meetings with DiaMedica Therapeutics (DMAC) management at these conferences?
